FDA Ad Com thumbs down on Neovasc Reducer

• Thinly traded nano cap Neovasc (NASDAQ:NVCN) slumps 36% premarket on increased volume in reaction to yesterday's FDA advisory committee vote of 13-3 (2 abstained) against approval of its Reducer for the treatment of certain refractory angina patients.
• CEO Fred Colen says, “We would like to thank the FDA, the panel and members of the public that offered their insights during yesterday’s Circulatory System Devices Advisory Panel meeting. Clearly, we are disappointed with the meeting’s outcome and we will provide further updates in the coming weeks.”
• Reducer, an hour-glass-shaped stent-like device that is implanted in the large vein that drains blood from the heart muscle, was CE Mark-certified in November 2011.
• https://seekingalpha.com/news/3627113-fda-ad-com-thumbs-down-on-neovasc-reducer-shares-plummet-36